

# SECURITIES AND EXCHANGE COMMISSION

## FORM 6-K

Current report of foreign issuer pursuant to Rules 13a-16 and 15d-16 Amendments

Filing Date: **2003-02-10** | Period of Report: **2003-02-10**

SEC Accession No. **0000902561-03-000051**

([HTML Version](#) on [secdatabase.com](#))

### FILER

#### **CAMBRIDGE ANTIBODY TECHNOLOGY GROUP PLC**

CIK: **1067386** | IRS No.: **000000000** | Fiscal Year End: **1231**  
Type: **6-K** | Act: **34** | File No.: **000-31116** | Film No.: **03547143**  
SIC: **8731** Commercial physical & biological research

Mailing Address  
*SCIENCE PARK MELBOURN  
CAMBRIDGESHIRE U K  
SG8 6JJ*

Business Address  
*SCIENCE PARK MELBOURN  
CAMBRIDGESHIRE U K  
SG8 6JJ A1  
011-44-1763-263233*

SECURITIES AND EXCHANGE COMMISSION  
WASHINGTON, DC 20549

FORM 6-K

REPORT OF FOREIGN PRIVATE ISSUER  
PURSUANT TO RULE 13a-16 OR 15d-16 OF  
THE SECURITIES EXCHANGE ACT OF 1934

February 10, 2003

Cambridge Antibody Technology Group PLC  
(Translation of Registrant's Name Into English)

Milstein Building, Granta Park, Cambridge, CB1 6GH, England  
(Address of Principal Executive Offices)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F

Form 20-F  Form 40-F

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7):

Indicate by check mark whether by furnishing the information contained in this Form, the registrant is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2 (b) under the Securities Exchange Act of 1934.

Yes  No

If "Yes" is marked, indicate below the file number assigned to the registrant in connection with Rule 12g3-2 (b): 82- \_\_\_\_\_

EXHIBIT INDEX

-----

This filing contains the following exhibits.

EXHIBIT

-----

DESCRIPTION

-----

99.1

Press release dated February 7, 2003  
announcing outcome of the registrant's  
annual general meeting.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

Date: 10 February 2003

Cambridge Antibody Technology Group PLC

By: /s/ Rowena Gardner

-----  
Name: Rowena Gardner

Title: Director of Corporate Communications

02/CAT/06

Page 1 of 2

FOR IMMEDIATE RELEASE

15.30 GMT 10.30 EST Friday 7 February 2003

For Further Information Contact:

Cambridge Antibody Technology

Tel: +44 (0) 1223 471 471

Peter Chambre, Chief Executive Officer

John Aston, Chief Financial Officer

Rowena Gardner, Director of Corporate Communications

Weber Shandwick Square Mile (Europe)

Tel: +44 (0) 20 7067 0700

Kevin Smith

Graham Herring

BMC Communications/The Trout Group (USA)

Tel: +1 212 477 9007

Brad Miles, ext. 17 (media)

Brandon Lewis, ext. 15 (investors)

CAMBRIDGE ANTIBODY TECHNOLOGY GROUP PLC

REPORTS OUTCOME OF ANNUAL GENERAL MEETING

Cambridge, UK...Cambridge Antibody Technology (LSE: CAT, NASDAQ: CATG) reports that at its Annual General Meeting, held at 12:30 GMT on Friday 7 February 2003, all resolutions were duly passed.

-ENDS-

Notes to Editors:

Cambridge Antibody Technology (CAT)

- o CAT is a UK-based biotechnology company using its proprietary technologies and capabilities in human monoclonal antibodies for drug discovery and drug development. Based near Cambridge, England, CAT currently employs around 290 people.
- o CAT is a leader in the discovery and development of human therapeutic antibodies and has an advanced proprietary platform technology for rapidly isolating human monoclonal antibodies using phage display systems. CAT has extensive phage antibody libraries, currently incorporating more than 100 billion distinct antibodies. These libraries form the basis for the Company's strategy to develop a portfolio of antibody-based drugs.
- o Humira<sup>TM</sup>, the leading CAT-derived antibody, isolated and optimised in collaboration with Abbott, has been approved by the US Food and Drug Administration for marketing in the US as a treatment for rheumatoid arthritis. Six further CAT-derived human therapeutic antibodies are at

various stages of clinical trials.

- o CAT has alliances with a large number of pharmaceutical and biotechnology companies to discover, develop and commercialise human monoclonal antibody-based products. CAT has also licensed its proprietary human phage antibody libraries to several companies for target validation and drug discovery. CAT's collaborators include: Abbott, Amgen, Amrad, Chugai, Elan,

Page 2 of 2

Genzyme, Human Genome Sciences, Merck & Co, Pharmacia and Wyeth Research.

- o CAT is listed on the London Stock Exchange and on NASDAQ since June 2001. CAT raised (pound)41m in its IPO in March 1997 and (pound)93m in a secondary offering in March 2000.

Application of the Safe Harbor of the US Private Securities Litigation Reform Act of 1995: This press release contains statements about CAT that are forward looking statements. All statements other than statements of historical facts included in this press release may be forward looking statements within the meaning of Section 21E of the US Securities Exchange Act of 1934.

These forward looking statements are based on numerous assumptions regarding CAT's present and future business strategies and the environment in which CAT will operate in the future. Certain factors that could cause CAT's actual results, performance or achievements to differ materially from those in the forward looking statements include: market conditions, CAT's ability to enter into and maintain collaborative arrangements, success of product candidates in clinical trials, regulatory developments and competition.